Morgan Stanley Downgrades Inspire Pharmaceuticals (ISPH) to Underweight
More News related to ISPH
- Inspire Announces Webcast of Presentation at Piper Jaffray Conference
- Inspire Pharmaceuticals (ISPH) Beats Q3 View By 5c; Guides Down
- Inspire Reports Third Quarter 2008 Financial Results
- Beacon Equity Issues Technical Trade Alerts on Market Movers: ECOS, ALGN, ISPH, SIMG, IDTI, EXEL
- Inspire Announces New Data from Denufosol Phase 3 Program at North American Cystic Fibrosis Conference
More News related to Downgrades
- B. Riley Downgrades Doral Financial (DRL) to Neutral
- CL King Downgrades Ceragon (CRNT) to Accumulate
- Matrix Upgrades/Downgrades for December 1, 2008
- Raymond James Downgrades Allscripts (MDRX) to Market Perform
- RBC Capital Downgrades Strategic Hotels & Resorts (BEE) to Underperform
Morgan Stanley downgrades Inspire Pharmaceuticals (Nasdaq: ISPH) from Equalweight to Underweight.
Inspire Pharmaceuticals, Inc. (Inspire) is a biopharmaceutical company focusing on discovering, developing and commercializing prescription pharmaceutical products in disease areas with commercial potential or unmet medical needs.
Related Categories
DowngradesStocks Mentioned
-0.31Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
